EMA Authorised: Lytgobi (Futibatinib) — Taiho Pharma Netherlands B.V.

View source ↗

Summary

EU authorises Lytgobi (futibatinib) for cholangiocarcinoma with conditional approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Lytgobi (Futibatinib)

Snippet

Status: Authorised. Therapeutic area: Cholangiocarcinoma. MAH: Taiho Pharma Netherlands B.V.. Decision date: 18/09/2025. Conditional approval